Search our Database of Scientific Publications and Authors

I’m looking for a

    1941 results match your criteria Allergy and Asthma Proceedings[Journal]

    1 OF 39

    A review of the efficacy and safety of once-daily tiotropium Respimat 2.5 micrograms in adults and adolescents with asthma.
    • Authors:
    Allergy Asthma Proc 2017 Nov 6. Epub 2017 Nov 6.
    Background: Despite current guidelines, many patients with asthma remain symptomatic, particularly those intolerant of,unresponsive to, or uncontrolled by long-acting beta 2-agonists (LABAs). Tiotropium bromide, delivered through the Respimatsoft-mist inhaler in 2 puffs of 1.25 micrograms each, is approved for the long-term, maintenance treatment of asthma in patients aged greater than or equal to 6 years. Read More

    The role of intravenous access during oral food challenges in food protein-induced enterocolitis syndrome.
    Allergy Asthma Proc 2017 Nov;38(6):467-473
    Background: Food protein-induced enterocolitis syndrome (FPIES) is a non-immunoglobulin E mediated food hypersensitivity syndrome characterized by profuse vomiting and diarrhea, which leads to lethargy, dehydration, and hypotension. Given the potential severity of reactions, resolution of FPIES is confirmed via oral food challenge (OFC) during which intravenous (IV) access is recommended to facilitate IV fluids (IVF) and steroid therapy. Risk factors for IV treatment are not well characterized. Read More

    Health-related quality of life in Danish children with hereditary angioedema.
    Allergy Asthma Proc 2017 Nov;38(6):440-446
    Background: The potentially life-threatening disease hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) can have considerable impact on the health-related quality of life (HRQoL) in adult patients. Half the patients with C1-INH-HAE develop symptoms before the age of 10 years. However, the HRQoL in children with C1-INH-HAE is almost unexplored. Read More

    Management of adverse reactions to biologic agents.
    Allergy Asthma Proc 2017 Nov;38(6):409-418
    Hypersensitivity reactions (HSR) to targeted biologic agents present as immediate reactions during infusion or as delayed reactions (after one or more exposures). The new classification includes phenotypes, endotypes, and biomarkers. Phenotypes include immediate type I (immunoglobulin E [IgE] or non-IgE mediated), cytokine release, mixed (type I/cytokine), and immune complexes type III (IgG mediated) reactions as well as delayed type IV reactions. Read More

    Interleukin 31 and skin diseases: A systematic review.
    Allergy Asthma Proc 2017 Nov;38(6):401-408
    Background: Although the pathophysiology of pruritus has been extensively studied in recent years, with many resultant advancements, management of pruritus is still enigmatic, particularly in chronic cutaneous diseases, such as atopic dermatitis, chronic urticaria, allergic contact dermatitis, cutaneous T-cell lymphoma, and uremic pruritus. The recent finding of the involvement of interleukin (IL) 31 in the pathogenesis of chronic pruritus has provided a novel approach to the management of chronic inflammatory skin disorders. The present report provided an in-depth overview of the role of IL-31 in chronic skin diseases and the possible diagnostic and therapeutic applications in the management of these diseases. Read More

    High adherence to subcutaneous immunotherapy in a real-life study from a large tertiary medical center.
    Allergy Asthma Proc 2017 Nov;38(6):78-84
    Background: Studies on real-life adherence to subcutaneous allergen immunotherapy (SCIT) for respiratory allergy are scarce. The aim of this study was to evaluate adherence to SCIT.

    Methods: The patients prescribed SCIT for allergic rhinitis and/or asthma in 2009-2011 were contacted in 2014 and asked whether they completed at least the 3 years of SCIT and/or whether they suspended the treatment for at least 2 months. Read More

    Association of imbalance of effector T cells and regulatory cells with the severity of asthma and allergic rhinitis in children.
    Allergy Asthma Proc 2017 Nov;38(6):70-77
    Purpose: This study investigated the frequency and absolute numbers of different subsets of peripheral blood cells, including CD4+ T cells and CD19+ interleukin (IL) 10+ B regulatory cells (Breg) and their potential association with clinical laboratory measurements in children diagnosed with simple asthma or asthma plus allergic rhinitis (AR).

    Method: The frequency and numbers of peripheral blood CD4+ interferon (IFN) gamma+ T-helper (Th) type 1, CD4+ IL-4+ Th2, CD4+ IL-17A+ Th17, CD4+CD25+ Forkhead Box P3+ regulatory T cells (Treg) and CD19+ IL-10+ Bregs in 22 children with asthma, 17 children with asthma and AR, and 25 healthy controls were determined by flow cytometry. The levels of serum cytokines were determined by enzyme-linked immunosorbent assay. Read More

    Systemic inflammation mediates the detrimental effects of obesity on asthma control.
    Allergy Asthma Proc 2017 Oct 2. Epub 2017 Oct 2.
    Background: Obesity negatively impacts asthma control, but the inflammatory mechanisms are poorly understood.

    Objective: To explore which systemic inflammatory mediators mediate the effects of obesity on asthma control.

    Methods: The subjects with stable asthma (n = 108) underwent assessment of clinical characteristics, which included usingThe Asthma Control Questionnaire (ACQ)-6. Read More

    Recombinant human C1 esterase inhibitor for acute hereditary angioedema attacks with upper airway involvement.
    Allergy Asthma Proc 2017 Nov 13;38(6):462-466. Epub 2017 Sep 13.
    Background: Recombinant human C1 esterase inhibitor (rhC1-INH) is approved for treatment of hereditary angioedema (HAE) in adolescents and adults. HAE attacks that involve the upper airway can be life threatening, and data on the administration of rhC1-INH for these types of attacks are currently limited.

    Objective: To evaluate the efficacy and safety of rhC1-INH for treatment of acute HAE attacks with upper airway involvement. Read More

    Evaluation of beclomethasone dipropionate (80 and 160 micrograms/day) delivered via a breath-actuated inhaler for persistent asthma.
    Allergy Asthma Proc 2017 Nov 8;38(6):419-430. Epub 2017 Sep 8.
    Background: Breath-actuated inhalers (BAI) may simplify the delivery of inhaled medications compared with other devices.

    Objective: To evaluate the efficacy and safety of beclomethasone dipropionate BAI versus matching placebo in adolescent and adult patients with persistent asthma.

    Methods: This phase III, 12-week, double-blind study enrolled patients with asthma aged ≥12 years who were previously treated with a stable dose of inhaled corticosteroid or noncorticosteroid therapy. Read More

    Efficacy of recombinant human C1 esterase inhibitor for the treatment of severe hereditary angioedema attacks.
    Allergy Asthma Proc 2017 Nov 5;38(6):456-461. Epub 2017 Sep 5.
    Background: Severe attacks of hereditary angioedema (HAE) are debilitating and potentially life threatening, and can increase anxiety and the use of medical resources.

    Objective: This post hoc assessment evaluated recombinant human C1 esterase inhibitor (rhC1-INH) used to treat acute severe HAE attacks.

    Methods: In a double-blind, randomized-controlled trial (RCT), patients with an HAE attack (baseline visual analog scale score of ≥50 mm, with severe attacks defined as ≥75 mm) were randomly assigned to receive rhC1-INH (50 IU/kg for patients who weighed <84 kg; 4200 IU for patients who weighed ≥84 kg) or placebo. Read More

    Health-related quality of life in relation to disease activity in adults with hereditary angioedema in Sweden.
    Allergy Asthma Proc 2017 Nov 30;38(6):447-455. Epub 2017 Aug 30.
    Background: Health-related quality of life (HR-QoL) is impaired in patients with hereditary angioedema (HAE) but has not yet been satisfactorily described.

    Objective: To study HR-QoL in patients with HAE by combining different HR-QoL instruments with disease activity assessment.

    Methods: All adults in the Swedish HAE registry were invited to take part in this questionnaire study, which used the generic HR-QoL instruments, EuroQol 5 Dimensions 5 Level (EQ-5D-5L) and the RAND Corporation Short Form 36 (RAND-36), the disease-specific Angioedema Quality of Life instrument (AE-QoL), the recently introduced Angioedema Activity Score (AAS) form, and questionnaires on sick leave and prophylactic medication. Read More

    Skin rash in a 2-week-old infant.
    Allergy Asthma Proc 2017 09;38(5):390-393
    We presented a case of a male infant with annular patchy rash on his torso since 2 weeks of age. This was initially diagnosed as tinea corporis but did not respond to oral antifungal treatment. Because of the appearance of the rash and a history of a certain disease in a maternal aunt, we suspected the most probable cause of the rash and the diagnosis was confirmed by laboratory testing. Read More

    The risk of autoimmune connective tissue diseases in patients with atopy: A nationwide population-based cohort study.
    Allergy Asthma Proc 2017 Sep;38(5):383-389
    Background: The relationship between autoimmune connective tissue disease (ACTD) and atopy is controversial.

    Objectives: To investigate the risks of ACTDs in patients with atopic triad diseases, including atopic dermatitis, allergic rhinitis, and asthma, by using a nationwide data base.

    Methods: A cohort of 155,311 patients newly diagnosed with atopic dermatitis, allergic rhinitis, or asthma in 2002-2011 was obtained from the Taiwan National Health Insurance Research Database. Read More

    Frequency of selective immediate responders to aminopenicillins and cephalosporins in Turkish children.
    Allergy Asthma Proc 2017 Sep;38(5):376-382
    Background: Beta-lactam antibiotics (BLA) are the most commonly prescribed antibiotics and are responsible for the majority of immediate hypersensitivity reactions to drugs in children. Cross-reactivity is important in hypersensitivity to BLAs because these drugs all share a common beta-lactam structure and some share similar side chains.

    Objective: The aim of this study was to evaluate the clinical characteristics of patients who are diagnosed with immediate-type BLA hypersensitivity and frequency of patients with side chain hypersensitivity, "selective responders. Read More

    Association of aeroallergen sensitization and atopic disease in the Sonoran Desert.
    Allergy Asthma Proc 2017 Sep;38(5):370-375
    Background: Numerous aeroallergens have been associated with the development of asthma, including Alternaria, house-dust mite, and pet dander. Tucson, Arizona, is located in the Sonoran Desert, which has the highest diversity of vegetation of any desert in the world. Given the unique pollen profile in this region, we sought to identify the most common aeroallergens associated with rhinitis and asthma diagnosis in the local adult population. Read More

    Pneumococcal 13-valent conjugate vaccine administration after inferior response to pneumococcal vaccine.
    Allergy Asthma Proc 2017 Sep;38(5):365-369
    Background: The pneumococcal vaccine, a nonconjugated vaccine, may be used to evaluate the integrity of the humoral immune system. Those patients with an inferior response to a nonconjugated vaccine may be vaccinated with a conjugated vaccine, which elicits both a B- and T-cell response.

    Objective: We evaluated the immunogenicity of a conjugated vaccine in patients with inferior responses to a nonconjugated vaccine. Read More

    Der p 1 and Der p 2 specific immunoglobulin E measurement for diagnosis of Dermatophagoides pteronyssinus allergy: A systematic review and meta-analysis.
    Allergy Asthma Proc 2017 Sep;38(5):333-342
    Background: A clinical history of allergic symptoms and a skin-prick test with house-dust mite crude extracts are standard diagnostic procedures for Dermatophagoides pteronyssinus allergy. Specific immunoglobulin E (IgE) responses to Der p 1 and Der p 2 allergens have been used for the diagnosis of D. pteronyssinus allergy; however, evaluation of the diagnostic performance of Der p 1 and Der p 2 specific IgE (sIgE) produced inconsistent findings. Read More

    Pre- and postoperative blood neutrophil-to-lymphocyte and eosinophil-to-lymphocyte ratios in patients with sinonasal polyps: A preliminary investigation.
    Allergy Asthma Proc 2017 Sep;38(5):64-69
    Background: Identifying specific endotypes within the broad picture of chronic rhinosinusitis with nasal polyps (CRSwNP), by using biomarkers for instance, remains a challenge. The prognostic role of the neutrophil-to-lymphocyte ratio (NLR) and the eosinophil-to-lymphocyte ratio (ELR) as potential markers of inflammation has already been discussed.

    Objective: The aim of the present study was to compare NLR and ELR before and after endoscopic sinus surgery (ESS) and nasal mometasone furoate for CRSwNP by stratifying patients by their clinical and histologic features. Read More

    Characteristics of drug-induced anaphylaxis in children and adolescents.
    Allergy Asthma Proc 2017 Sep;38(5):56-63
    Background: Although data on anaphylaxis in the general population exist for different allergens, there is still lack of detailed etiologic data on drug-induced anaphylaxis (DIA), particularly in children.

    Objective: To define the etiology of DIA, to determine the accuracy of drug-related anaphylaxis histories, along with the severity and culprit drug associations among individuals <18 years old.

    Methods: Patients with a history of drug hypersensitivity reaction (DHR) referred to our center between January 2012 and February 2016 were included. Read More

    Indicators of poorly controlled asthma and health-related quality of life among school-age children in the United States.
    Allergy Asthma Proc 2017 Nov 11;38(6):431-439. Epub 2017 Aug 11.
    Background: Poorly controlled asthma has far-reaching effects on school-age children and their parents, but little is known about the national impact on health-related quality of life (HRQoL).

    Objective: To examine HRQoL associated with asthma and indicators of poorly controlled asthma in the United States.

    Methods: This was a cross-sectional analysis of HRQoL among school-age children (age range, 6-17 years) with asthma in the nationally representative 2007-2013 Medical Expenditure Panel Survey (MEPS). Read More

    Efficacy and safety of beclomethasone dipropionate breath-actuated or metered-dose inhaler in pediatric patients with asthma.
    Allergy Asthma Proc 2017 Sep 14;38(5):354-364. Epub 2017 Jul 14.
    Background: Breath-actuated inhalers (BAI) eliminate the need for hand-breath coordination and, therefore, simplify the delivery of inhaled medication.

    Objective: To evaluate the efficacy and safety of beclomethasone dipropionate BAI and metered-dose inhaler (MDI) versus placebo in pediatric patients ages 4-11 years with persistent asthma.

    Methods: In this double-blind, double-dummy, phase III study, 628 children with persistent asthma were randomly assigned (1:1:1:1:1) to twice-daily beclomethasone dipropionate (BAI 80 μg/day, BAI 160 μg/day, MDI 80 μg/day, or MDI 160 μg/day) or to placebo. Read More

    A 28-year-old woman with fever, rash, and pancytopenia.
    Allergy Asthma Proc 2017 Jul;38(4):322-327
    A 28-year-old Hispanic woman was admitted to the hospital with fever, sore throat, arthralgia, and a generalized rash of 2 weeks' duration. Her medical history was significant for various food and medication allergies. Multiple antibiotics were given for suspected infection, and she subsequently developed a new skin rash, acute liver injury, eosinophilia, and pancytopenia. Read More

    Pearls and pitfalls: Autoimmune lymphoproliferative syndrome and autoimmune lymphoproliferative syndrome-like disease.
    Allergy Asthma Proc 2017 Jul;38(4):317-321
    A case of autoimmune lymphoproliferative syndrome (ALPS) was presented, followed by a discussion of the clinical characteristics, pathophysiology, diagnosis, and management of this disease. Clinical pearls and pitfalls are emphasized for the use of the practicing allergist and the fellow in-training. The diagnosis of ALPS was guided by published criteria. Read More

    A 10-year experience of a novel and safe modified environmental rush immunotherapy protocol.
    Allergy Asthma Proc 2017 Jul;38(4):309-316
    Background: Allergen immunotherapy (AIT) is an effective treatment option for allergic rhinitis. Although conventional AIT takes 6 months to reach maintenance dosing, rush AIT accelerates the build-up period and reaches the maintenance dose months earlier. However, accelerated schedules of AIT carry an increased risk of systemic reactions (SR). Read More

    Association of maternal depression and allergic diseases in Korean children.
    Allergy Asthma Proc 2017 Jul;38(4):300-308
    Purpose: An association between childhood allergic disease and parental psychological disorders has been reported. However, little is known about the relationship between childhood allergic disease and maternal depression. This study was performed to determine if there is an association between childhood allergic disease and maternal depression. Read More

    Seasonal variation and monthly patterns of skin symptoms in Korean children with atopic eczema/dermatitis syndrome.
    Allergy Asthma Proc 2017 Jul;38(4):294-299
    Background: There have been controversies about the seasonality in aggravation of atopic eczema/dermatitis syndrome (AEDS) symptoms, although understanding the seasonal patterns of AEDS symptoms is an important step in preventing exacerbation through proactive management.

    Objective: The aim of this study was to evaluate whether there are seasonal variations or monthly patterns of symptoms in children with AEDS.

    Methods: A total of 590 children with AEDS (median age, 21 months) were enrolled and were followed up for at least 1 year between August 2012 and March 2015. Read More

    Prevalence and triggers of anaphylactic events in schools.
    Allergy Asthma Proc 2017 Jul;38(4):286-293
    Background: Prevention and management of anaphylaxis in schools is an area of active interest as allergy and asthma rates in children continue to increase. A greater understanding of the prevalence and characteristics of anaphylaxis can help guide preventive and management strategies both within and outside of the school setting, with the goal of reducing morbidity and mortality.

    Objective: This study was performed to elucidate the epidemiology of and management strategies for anaphylaxis in the school setting. Read More

    Asthma in older people hospitalized with influenza in Spain: A case-control study.
    Allergy Asthma Proc 2017 Jul;38(4):277-285
    Background: Influenza infection is an exacerbating factor for asthma, and its prevention is critical in older patients with asthma.

    Objective: This study investigated the association between asthma and influenza-related hospitalization, in Spain, of patients ages ≥ 65 years and their clinical evolution.

    Methods: A multicenter case-control study was carried out in 20 Spanish hospitals during the 2013-2014 and 2014-2015 influenza seasons. Read More

    Atopic dermatitis treatment: Current state of the art and emerging therapies.
    Allergy Asthma Proc 2017 Jul;38(4):243-249
    Background: Atopic dermatitis (AD) can be debilitating and often requires the use of combination topical and systemic therapy to achieve adequate disease control.

    Methods: A non-systematic review was performed of current state of the art and emerging therapies for AD.

    Results: There are a number of topical agents approved by the U. Read More


    Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma.
    Allergy Asthma Proc 2017 Sep 21;38(5):343-353. Epub 2017 Jun 21.
    Background: A novel, inhalation-driven, multidose dry powder inhaler (MDPI) has been developed, which allows for lower doses of fluticasone propionate (Fp) and Fp/salmeterol (FS) for the treatment of patients with asthma.

    Objective: This phase III, multicenter, double-blind, parallel-group study (NCT02141854) evaluated the efficacy and safety of Fp MDPI and FS MDPI versus placebo MDPI.

    Methods: Patients aged ≥12 years with persistent asthma who previously took an inhaled corticosteroid with or without a long-acting beta-agonist entered a 14- to 21-day run-in period, during which they received single-blind, low-dose Fp MDPI 50 μg (1 inhalation twice daily [b. Read More

    Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.
    Allergy Asthma Proc 2017 Jul 19;38(4):250-263. Epub 2017 Jun 19.
    Background: There are limited pediatric data about the use of omalizumab, especially the effectiveness and safety of omalizumab in the real-world management of allergic asthma.

    Objective: The objective of this study was to summarize the safety and efficacy of omalizumab in both randomized clinical trials (RCT) used for U.S. Read More

    A 6-month safety and efficacy study of fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers in persistent asthma.
    Allergy Asthma Proc 2017 Jul 24;38(4):264-276. Epub 2017 May 24.
    Background: A novel multidose dry powder inhaler (MDPI) that is breath actuated, easy, and intuitive to use has been developed for administering fluticasone propionate (Fp) and Fp/salmeterol (FS).

    Objective: To assess the safety and efficacy of Fp MDPI versus Fp hydrofluoroalkane (HFA) and FS MDPI versus FS dry-powder inhaler (DPI).

    Methods: This phase III, 26-week, open-label, active drug-controlled study enrolled subjects ≥12 years old with persistent asthma. Read More

    A 30-year-old woman with chronic hives, intermittent fevers, and joint pain.
    Allergy Asthma Proc 2017 May;38(3):231-235
    Chronic urticaria with concomitant systemic symptoms may be seen in several rheumatologic and autoinflammatory conditions. Although most of these conditions tend to improve with corticosteroids, symptoms often recur with dose tapering. The appearance of the rash in addition to the symptom pattern and laboratory data must be considered to differentiate potential causes. Read More

    Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis.
    Allergy Asthma Proc 2017 May;38(3):222-230
    Background: Pharmacologic treatment is a mainstay of allergy therapy and many caregivers use over-the-counter antihistamines for the treatment of seasonal allergic rhinitis (SAR) symptoms in children.

    Objective: To assess the efficacy and safety of cetirizine 10 mg syrup versus loratadine 10 mg syrup versus placebo syrup in a randomized double-blind study of children, ages 6-11 years, with SAR.

    Methods: This randomized, double-blind, parallel-group, placebo-controlled study was conducted at 71 U. Read More

    Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema.
    Allergy Asthma Proc 2017 May;38(3):216-221
    Background: Increased estrogen levels during pregnancy can exacerbate hereditary angioedema (HAE), yet disease and treatment ramifications remain poorly studied in pregnant women.

    Objective: Data from the international Berinert Patient Registry were used to evaluate outcomes of pregnancies exposed to plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH) during routine HAE management.

    Methods: This observational registry, conducted between 2010 and 2014 at 30 U. Read More

    In vitro impact of anti-immunoglobulin E monoclonal antibodies, including omalizumab on whole blood basophil histamine release: Assessment of direct induction of basophil histamine release and evaluation of modulation of allergen-induced basophil histamine release.
    Allergy Asthma Proc 2017 May;38(3):204-215
    Aim: The aim of this study was to evaluate the potential of anti-immunoglobulin E (IgE) and/or anti-IgE-IgE immune complexes to release histamine from peripheral blood basophils. In addition, a potential modulating effect of anti-IgE-IgE complexes on allergen-induced peripheral blood basophil histamine release was evaluated.

    Methods: Whole blood basophil histamine release (WBB-HR) tests done by using glass-fiber-based microtiter plates were performed in 62 patients with allergic rhinitis and/or asthma sensitized to perennial allergens. Read More

    High mobility group box 1: Biomarker of inhaled corticosteroid treatment response in children with moderate-severe asthma.
    Allergy Asthma Proc 2017 May;38(3):197-203
    Background: High mobility group box 1 (HMGB1) is abnormally expressed in serum and sputum of patients with allergic asthma.

    Objective: The aim of this study was to investigate the role of HMGB1 as guidance for treatment management of children with asthma.

    Methods: Thirty children with asthma and 44 healthy children were enrolled. Read More

    1 OF 39